explore -WSS

explore

author：entertainment 2025-10-02 11:10:10 - browse：72

Vivistim and Lead — A small Texas company is testing whether pairing vagus nerve stimulation with rehabilitation exercise can restore movement in people who have had a stroke. STAT/MicroTransponder, Inc.

Despite being forced by Hurricane Irma to close its outpatient facilities for several days, the Mayo Clinic in Jacksonville, Fla., is expected to forge ahead this month with a pivotal clinical trial testing whether an electrical implant can rewire the brains of stroke patients so they can use their arms and hands again.

If the patients who receive implants regain significantly more function than those who get only standard rehabilitation, it will show that stroke-damaged brain circuits can be bypassed like shorts in a circuit board, with healthy neurons coaxed into performing the job of those fried by stroke.

Although the results might not be make-or-break for the little 11-year-old Texas company sponsoring the trial (called MicroTransponder, the company’s also testing whether an electrical implant can alleviate tinnitus), there will be more evidence of whether “electroceuticals” — electrical stimuli tailored to treat diseases — work beyond their current use in controlling pain and a few other conditions or will fall short of the buzz surrounding them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Chemotherapy drug shortage eases slightly but still widespread

explore

focus

leisure time

WSS

How medical schools plan to diversify without affirmative action

Why Charlie Gard's case is so disturbing to Americans

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Pig kidney works a record two months in donated body

Telehealth for opioid use disorder is lifesaving

Was Amgen transparent enough on FDA's concern on cancer drug?

leisure time

explore

hotspot

Alkermes shareholders re

IRA could hurt research into orphan drugs for rare diseases

Virginia high school admissions case could be legal follow

Phenylephrine and the overlooked value of the placebo effect

Moonlake's readout produced a cash windfall. Risks remain

PEPFAR is under serious threat — and so is global health

New air purifier tech could be key to improving indoor air quality

Stroke deaths set to near 10 million globally by 2050

Heart attack and stroke risk calculators need revising

A common UTI test for kids haunts adults as a traumatic 'nightmare'

knowledge

Why age limits for politicians are a terrible idea

Pig kidney works a record two months in donated body

Telehealth for opioid use disorder is lifesaving

FDA rejects Alnylam's heart disease treatment over insufficient data

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Physician executives need more than on

explore

focus

leisure time

leisure time